In short
This Bloomberg Businessweek Daily episode is mainly about three separate stories. First, a federal judge in Oakland, California temporarily paused Paramount Skydance’s $110B takeover of Warner Bros. Discovery for 14 days, after attorneys general sued despite DOJ approval and expected EU clearance. The sticking point is antitrust/market consolidation concerns; the combined studios allegedly couldn’t reach 30% market share, which investors found less alarming. Paramount hopes to close by July 22, but the injunction could extend through trial and potentially lead to appeals, even the Supreme Court.
Guest
Chris Paul Mayer (Bloomberg News senior editor, entertainment team leader) explains the legal timeline and market reaction. Second, Isabelle Lee (Bloomberg cross-asset reporter) discusses a “peptide craze,” including gray-market peptide purchases and crypto use; she cites Chainalysis’s tracking of a 700% year-over-year increase in crypto-linked peptide buying. Third, Avalon Purnell (Bloomberg equities reporter) covers Martin Shkreli’s return, including his live-streaming and pursuit of a presidential pardon after lifetime pharma and securities bans.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Chapters
Tap a time to open that second in VOAnalysis of Paramount-Warner Bros. Merger Pause
0:00 to 1:24
Discussion on the federal judge's pause on the Paramount-Warner Bros. merger.
“So there's a lot of noise about AI, but time's too tight for more promises.”
Analysis of Paramount-Warner Bros. Merger Pause
1:28 to 2:01
Discussion on the federal judge's pause on the Paramount-Warner Bros. merger.
“As industries evolve faster than ever, companies need an environment that accelerates strategic growth and Michigan delivers on that promise.”
Analysis of Paramount-Warner Bros. Merger Pause
2:29 to 3:56
Discussion on the federal judge's pause on the Paramount-Warner Bros. merger.
“Federal judge temporarily paused Paramount Skydance's$110 billion takeover of Warner Brothers Discovery.”
Concerns Over Antitrust Issues
3:56 to 5:50
Exploration of antitrust concerns related to the merger and market share.
“What's the whole – if they get – wait, wait.”
Regulatory Landscape and Future Implications
5:50 to 8:08
Discussion on regulatory challenges and potential future implications of the merger.
“I think they're making Delverham, their chief legal officer, suggest it could go to the Supreme Court.”
Regulatory Landscape and Future Implications
8:46 to 9:13
Discussion on regulatory challenges and potential future implications of the merger.
“This product is not intended to diagnose, treat, cure, or prevent any disease.”
Middle East Conflicts and U.S. Involvement
9:13 to 11:28
Insights into the changing dynamics of conflict in the Middle East.
“You're listening to the Bloomberg Business Week Daily Podcast.”
Israel's Role in Regional Dynamics
11:28 to 14:01
Exploration of Israel's influence in the current geopolitical landscape.
“economic issues, the fact that many of these countries are exporters of oil, that they're rent dependent countries.”
Israel's Regional Position and Future
14:01 to 16:36
Discussion on Israel's changing diplomatic relationships and the implications of ongoing wars.
“I mean, you know, you talk about alliances with Israel and others not.”
Iran's Distraction Amidst Conflict
16:37 to 18:31
Exploration of how war has shifted Iranian public focus and governmental control.
“It was one day, but I respect everybody who responded.”
Show all 18 chapters
Interview with Dina Esfendiari
18:32 to 19:00
Insightful conversation with Dina Esfendiari on Middle Eastern geopolitics.
“We know it's later over there in Geneva, but thank you so much.”
Interview with Dina Esfendiari
19:07 to 19:54
Insightful conversation with Dina Esfendiari on Middle Eastern geopolitics.
“If you're actively involved in your portfolio, you probably catch yourself repeating the same actions.”
Peptide Market Discussion
21:06 to 22:54
Exploring the rise of peptides and the gray market for health supplements.
“Listen on Apple CarPlay and Android Auto with the Bloomberg Business App.”
Crypto's Role in the Peptide Market
22:55 to 28:00
Analysis of cryptocurrency use for purchasing peptides from gray market vendors.
“I mean, it's not - Do you want your Timu peptides?”
The Evolving Landscape of Bitcoin and Peptides
28:00 to 31:12
Explore how Bitcoin is being used in unconventional ways, such as purchasing peptides.
“So I just think, you know, it's the reality, right, of Bitcoin increasingly or the reality that's used in kind of, you know, illegal transactions.”
The Evolving Landscape of Bitcoin and Peptides
31:20 to 32:07
Explore how Bitcoin is being used in unconventional ways, such as purchasing peptides.
“If you're actively involved in your portfolio, you probably catch yourself repeating the same actions.”
Martin Shkreli: The Return of Pharma Bro
33:10 to 40:46
A deep dive into Martin Shkreli's controversial rise and current activities.
“This product is not intended to diagnose, treat, cure, or prevent any disease.”
Martin Shkreli: The Return of Pharma Bro
42:23 to 42:54
A deep dive into Martin Shkreli's controversial rise and current activities.
“When you're running a business, the best days are the ones where priorities stay on track.”
Transcript
Automatic transcript. May contain errors.0:00So there's a lot of noise about AI, but time's too tight for more promises. So let's talk about results. At IBM, we work with our employees to integrate technology right into the systems they need. Now, a global workforce of 300 ,000 can use AI to fill their HR questions, resolving 94 % of common questions. Not noise. Proof of how we can help companies get smarter by putting AI where it actually pays off, deep in the work that moves the business. Let's create smarter business. When you're running a business, the best days are the ones where priorities stay on track. For midsize and large companies, that isn't always easy.
0:38Risk can touch multiple parts of an organization at the same time, often in ways that aren't immediately obvious. It might involve property, liability, or cyber. It could stem from regulatory requirements or challenges tied to a specific industry or the scale of an operation. At that level, managing risk becomes an ongoing discipline, not a one-time decision. At the Hartford, the focus is on helping businesses manage risk before it turns into something more disruptive. That means working with companies to identify where they're exposed, decide what matters most, and put practical standards in place so risk is managed as part of day-to-day operations.
1:14And when losses do happen, the Hartford can pair that risk control work with insurance coverage grounded in underwriting, risk engineering, and claims experience developed over time. Learn more at thehartford.com slash risk mitigation. As industries evolve faster than ever, companies need an environment that accelerates strategic growth and Michigan delivers on that promise. From emerging startups to global enterprises, Michigan offers what executives value most, a resilient, innovative ecosystem, diverse communities that attract top talent and a quality of life that supports work-life balance.
1:48With our unified Team Michigan approach, businesses scale faster and compete at the highest level. Michigan, pure opportunity. Seize your opportunity at michiganbusiness.org. Bloomberg Audio Studios, podcasts, radio, news. This is Bloomberg Business Week Daily, reporting from the magazine that helps global leaders stay ahead with insight on the people, companies and trends shaping today's complex economy. Plus, global business, finance and tech news as it happens. The Bloomberg Businessweek Daily Podcast with Carol Masser and Tim Stenevek on Bloomberg Radio. Well, certainly top of mind today. Federal judge temporarily paused Paramount Skydance's$110 billion takeover of Warner Brothers Discovery.
2:39The judge in Oakland, California ordering the companies to hold off on consummating the deal for 14 days. Paramount Warner Brothers hope to close, though, Tim, as soon as July 22nd. Yeah, shares dipped initially. Warner Brothers Discovery shares are still lower, down 3.8%. Paramount Skydance shares, they were down earlier in the session as much as 2%, but down now. A little bit higher. A little bit higher right now. Just a tad. All right, so let's get to it. What do we need to know? Why is this happening now? That's what makes me wonder. Bloomberg News Senior Editor and Entertainment team leader, Chris Paul Mayer, usually on the West Coast, in the heart of Hollywood, out there in L.A., joining us here, as we said, in New York City.
3:19What do we know about this, and why is this happening now? Well, just to put a little context here, they were very close to closing this. Justice Department approved the merger. EU is expected to announce something on Wednesday. They're going to have a deal and greenlight it. So Paramount was hoping they could actually close this week. And so the attorneys general who've been sort of threatening action finally did sue. And so now this is a potential problem because anything past September that Paramount doesn't close, they have to pay Warner Brothers shareholders millions of dollars a day until they get it done, if they get it done.
3:56What's the whole – if they get – wait, wait. If they get it done, are we really saying that? Well, I think the market's reaction indicates that something will happen, that some sort of agreement will be reached. I think that might be a face-saving move for the attorneys general, certainly for Paramount as well. What's the sticking point here? Well, you know, there's a lot of people, particularly in Hollywood, who really object to this. I mean, we're combining two, you know, legendary movie studios, two giant operators of cable TV channels, two news divisions, CBS and CNN, two giant streaming services.
4:27So this is kind of this. If this isn't antitrust, I mean, you know, what is right? I mean, this is a major consolidation. Now you get into the question of how much market share do they have. And this is one of the things that I think people reacted. We're a little surprised that the suit wasn't stronger. They really decided to focus on the movie business. And they couldn't even really even get a 30 % market share for the combined studios. So I think there was a feeling that the case was not as strong as it might have been. And this is kind of like almost a relief for investors. So could any chance Netflix come in at this point, Chris?
5:05And would this be a deal that would more likely pass regulatory muster? Well, we can go on and on about Netflix right now. They're sort of in a lot of trouble. I mean, their stock really began to head south last year when they initially were interested in Warner Brothers. And they haven't really overcome this idea that what were they thinking, you know. So I can't see them coming back at this point. So this deal does get done? I mean, we know they want to do it as soon as July 22nd. Is that likely to happen, or is it just maybe a case of the law? Definitely not July 22nd. So I think the next is a hearing to determine whether the injunction that's just a temporary one now goes at least through the end of trial.
5:41Now, remember, the attorneys general are asking for a trial date next year. So, you know, that's potential trouble for Paramount. And they're going to fight every step of this the way. They're going to fight the injunction. I think they're making Delverham, their chief legal officer, suggest it could go to the Supreme Court. But I mean, if it goes to the Supreme Court, is there, I don't know, it's hard to say with this Supreme Court, but is there sort of precedent for something like this? I mean, it's a challenge to actually answer that, given that we're in a different era than we've ever seen with media right now.
6:14And, you know, if you were describing this 10 years ago, I think there would be huge issues. But it's not like that anymore. And by the way, make it to him, who is the antitrust chief in the first Trump administration who argued that AT &T should not be able to buy Time Warner. And he lost that case. Of course, now he's in favor of Warner Brothers consolidation. But I think, you know, most to your point, the Trump administration is seen as pretty pro merger. We heard the FCC commissioner on our program here recently saying that he was talking about all the deals. You know, he's he's got some final say in the in the Warner Brothers deal as well.
6:47But, you know, this is. And he was at the UFC fight on the White House line. I know. All we could go on and on about all the relationships with Paramount and the Trump administration, for sure. It's a saving face, maybe even what it's all about, like you said, too. All right. Chris Palmieri, thank you so much. So excited to have you here. Bloomberg News Media and Entertainment Team lead Chris Palmieri joining us here in our Bloomberg studio. Stay with us. More from Bloomberg Businessweek Daily coming up after this.
7:21Support for the show comes from public.com. If you're actively involved in your portfolio, you probably catch yourself repeating the same actions. Buying the dip, manually sweeping idle cash, putting on a hedge. On public, you can now create AI agents that handle all these tasks on your behalf. Just describe what you want to do in plain English. Like, if the VIX hits 25, buy a put option on the S &P 500. or if my cash balance goes above$20 ,000, move the excess into my direct index. You approve the workflow and your agent handles the rest. Monitoring the market, watching for your conditions and executing your strategies exactly as defined.
7:59An investing platform driven by your intent, not just your clicks. You can also get full read and write access to your account via the public API. Go to public.com slash market and fund your account in five minutes or less. That's public.com slash market. Paid for by Public Investing. Brokered services by Open to the Public Investing, Inc., Member FINRA, and SIPC. Advisory services by Public Advisors, LLC, SEC Registered Advisor. Complete disclosures available at public.com slash disclosures. If your best finance people are doing expense reports, chasing receipts, or spending time on month-end close, it's time to get Brex AF, a Gentic finance that eliminates that work before it starts.
8:43Learn more at brecks.com slash AF.
9:13This product is not intended to diagnose, treat, cure, or prevent any disease. You're listening to the Bloomberg Business Week Daily Podcast. Catch us live weekday afternoons from 2 to 5 Eastern. Listen on Apple CarPlay and Android Auto with the Bloomberg Business App. Or watch us live on YouTube. As Carol mentioned, so notes a recent Bloomberg Big Take that we wanted to share with everyone with more Bloomberg Economics GeoEconomics analysts focusing on the Middle East. Dina Esfandiari with us from Geneva, Switzerland. Dina is the author of New Order in the Gulf, The Rise of the UAE, and co-author of Triple Axies, Iran's Relations with Russia and China.
9:48She holds a PhD in the War Studies Department at King's College in London. As we mentioned, the U.S. conducting a ninth straight day of airstrikes on Iran. Why, Dina, should we be focusing on the longer array of actions and conflict to tell the story of a changing Middle East? because this is a region that has been filled with turmoil for as long as I can remember and beyond that and the last two three years have only worsened the instability that the Middle East has seen as we outline in the piece after October 7th and the war that Israel led against Gaza everything began to change alliances were reshaped in the Middle East partnerships changed, new wars erupted, new violence erupted.
10:39And unfortunately, none of that looks like it's going to be resolved anytime soon. Why? Is it just because it's been in conflict, this region, for so long? Does the U.S. attack have some role? Like, why are we here at this moment in time, Dina? An understandable question. And honestly, I could probably write another PhD on the answer, but in order to shorten it, I think various factors. I think foreign players, including the United States and others like Russia and China, have played a role in it. I think players within the Middle East have done very little to improve their situation. I think within countries in the Middle East, governance has been a real issue, which at time exacerbates both domestic crises and regional crises.
11:28Honestly, I could go on. economic issues, the fact that many of these countries are exporters of oil, that they're rent dependent countries. None of these factors have helped. And the tensions that have erupted in the last few years, really, they've exacerbated these problems. And again, there is no path right now to resolving any of them. So it raises the question about the U.S. role in the Middle East right now and what exactly the endgame is for the United States. And, you know, far be it for me to ask you to get inside the president's head and give us a prediction there. But I think a lot of people question the idea of a clean and quick end to at least the U.S.
12:11involvement with Iran. Is that fair to say? Absolutely. U.S. war goals have been changing since the war with Iran erupted. Initially, it was about regime change. Then it turned into degrading the Islamic Republic's capabilities. Now it's become opening a strait that was open before the war broke out. So it's really unclear what President Trump's objectives in this conflict are. But I think for now, those objectives have become very limited and they are primarily focused on the straits. It needs to be open. It needs to not be under Iranian control. And that is exactly what the Iranians are contesting.
12:54But that was how things were before the end of February. That's right. But they signed an MOU, a ceasefire of sorts, where they promised to continue negotiations to resolve some of the issues that plagued their relations, including Iran's nuclear program. But they didn't even get that far because within a few weeks, both sides had a different interpretation of the implementation of the MOU. The Iranians thought that the US was acting in bad faith by not implementing it properly, by, for example, opening up an alternative route in the Strait of Hormuz close to the Omani shore. And the Iranians felt that this was going against the MOU.
13:39And so they went forward with ensuring that they would be able to establish a clear red line. And that red line was that the Strait of Hormuz belongs to Iran and Iran must control it. Dina, speaking of lines, you guys write in this story, Israel has become another fault line and the relationship between the Gulf states shifted from neutrality to hostile, according to Bloomberg economics. I mean, you know, you talk about alliances with Israel and others not. Where is Israel in all of this? And how much is are they? I don't you know, their role in kind of creating kind of where we are today? Well, I would argue three years into a regional war, almost three years into a regional war, Israel is much worse off than it was at the outset.
14:28Before October 7th, there was a wave of Arab normalizations occurring with Israel. The UAE and Bahrain had already normalized, and there was real talk of Saudi Arabia, the crown jewels of normalization, also establishing ties with Israel. Now, a few years later, that is absolutely off the table. Saudi Arabia, even if it wanted to, even if the crown prince wanted to go ahead with normalization with Israel, he wouldn't be able to do it simply because domestically it is so taboo right now. And that really speaks to how the region views Israel. The populations, Arab populations in the Middle East view Israel, but also some of the leadership of the Gulf Arab states who now see Israel as a threat equal to, if not superior to Iran, because it is enabled by the United States in a way that Iran just simply isn't.
15:21So what fixes this diplomacy, war, war to the bitter end or nothing? You know, I did in a silly mood or just, I don't know, thinking about, oh, my gosh, you know, reading the headlines this morning, a poll on X. And I'm like, does it just kind of keep going on for a little bit longer? Does the war end soon? Or is it the forever war? Like, I don't know. Honestly, I think right now we are on track towards this becoming the beginning of another forever war. Both sides are being very stubborn in terms of ensuring the respect of their red lines in terms of shaping the negotiations. So they don't want to return to the negotiating table until those red lines have been established and the other side understands them.
16:09And neither side seems to want to de-escalate. And of course, the only way to end this, the only way to end this really is through diplomacy. More war will not resolve anything. It may destroy infrastructure. It may destroy capabilities. But at the end of the day, it will only give more bitterness, more anger amongst the leadership of the countries that are facing this kind of war and ensure that they rebuild And this all restarts again. And not scientific. I'm looking at my ex-poll. It was one day, but I respect everybody who responded. It was U.S. and Iran over soon, 13 percent continues to take longer, 42 percent forever war, 45 percent.
16:48So, Dina, they agree with you. Dina, what happened to the Iranians who in February the president thought would would rise up and would sort of lead a new government or at least show that there was some sort of resistance movement that that would would help to make a transition toward a country that at least this this United States government wants to see? Well, they've been distracted. They've been distracted by facing incoming bombs and missiles for the better part of the last two, three months that will ensure that the Iranian population doesn't focus on the shortcomings of their government, but rather on the fact that they are facing war and they are facing a dire economic situation and unemployment and hopelessness.
17:39So their attention has been refocused on something else. The other thing that's happened, and this is pretty normal for a wartime situation, is that war has allowed the Islamic Republic's leadership to regain control of the streets. Under the guise of war, they have reestablished checkpoints throughout the country. They have reestablished some control, ensuring that people no longer come out and demonstrate. So expressions of discontent have really been quelled, which means that essentially what this war did was by the government time. I'm looking forward to your next PhD paper because I am curious to see where this all goes.
18:21It's just pretty amazing. And just even also to see shifting U.S. sentiment when it comes to something like Israel. There's a lot of great statistics and research in this piece. Dina, we knew we wanted to talk to you, so thank you so much. We know it's later over there in Geneva, but thank you so much. Always, always appreciate your time. That, of course, is Dina Esfendiari. She is a geoeconomics analyst. She focuses specifically on the Middle East, so highly recommend to you check out this story by our team. It was a Bloomberg big take, and it is on the Bloomberg and at Bloomberg.com. She, of course, is with the Bloomberg economics team joining us from Geneva.
18:59Stay with us. More from Bloomberg Business Week Daily coming up after this.
19:06Support for the show comes from Public.com. If you're actively involved in your portfolio, you probably catch yourself repeating the same actions. Buying the dip, manually sweeping idle cash, putting on a hedge. On public, you can now create AI agents that handle all these tasks on your behalf. Just describe what you want to do in plain English. Like, if the VIX hits 25, buy a put option on the S &P 500. Or, if my cash balance goes above$20 ,000, move the excess into my direct index. You approve of the workflow and your agent handles the rest. Monitoring the market, watching for your conditions, and executing your strategies exactly as defined.
19:44An investing platform driven by your intent, not just your clicks. You can also get full read and write access to your account via the public API. Go to public.com slash market and fund your account in five minutes or less. That's public.com slash market. Paid for by Public Investing. Brokered services by Open to the Public Investing, Inc., member FINRA and SIPC. Advisory services by Public Advisors, LLC, SEC Registered Advisor. Complete disclosures available at public.com slash disclosures. If your best finance people are doing expense reports, chasing receipts, or spending time on month-end clothes, it's time to get Brex AF, a Gentic finance that eliminates that work before it starts.
20:28Learn more at brex.com slash AF. Aging doesn't stop, and neither should you, with Vital Proteins Collagen and Protein Shakes. Because around the age of 30, your body needs more support for movement and recovery. On workout and rest days, reach for a 30-gram total protein shake or go with our classic collagen peptides. Help support healthy hair, skin, nails, bones, and joints so you can stay vital, stay you. Visit vitalproteins.com to learn more and where to buy. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
21:02You're listening to the Bloomberg Business Week Daily Podcast. Catch us live weekday afternoons from 2 to 5 Eastern. Listen on Apple CarPlay and Android Auto with the Bloomberg Business App. Or watch us live on YouTube. Let's get to it with Isabelle Lee. She's Bloomberg News, Cross Asset Reporter. She joins us here in the Bloomberg Interactive Broker Studio. Why can't you buy... First of all, welcome. Great story. Congratulations. Thank you. Big compliments from you both. Well, we, you know, great stuff. Why can't you buy peptides with your credit card? I think, I mean, obviously if it's the accredited ones, you can.
21:37but then if it's like you mean a glp1 coming from like eli lily i don't even want to say legit but if it's like you know those kind of things you can well let's say maybe you could say if it's prescribed by a doctor it goes through the typical channels of yes you can use your typical channels you can use your so which peptides are we talking about here i think it's everything else other than if you know it then you can buy it with a credit card if you don't and if you can't pronounce it and if you can't read it you probably can't and i want to make a distinction between gray market and black market.
22:06Because when I was talking to my editors, they were like, black market? So gray market involves legal sale of authentic branded goods, and black market is illegal and prohibited. So this is gray market. Gray market. Okay. But these are unproven, and they're of unknown origin in some cases too, right? Yes, but I guess they're not yet explicitly banned. But in some cases, like, okay, you talk to this guy, Zach. He's 49 years old. He wants to use a peptide that he's told is an experimental weight loss drug. So essentially Eli Lilly is working on this thing. I think so. But he says like, I can get it already if I buy it from this other.
22:43Yes, and he can get it cheaper. I mean, the cost was$240 for roughly a year supply compared with$300 a month for something like if you buy it from a US reseller. So cost is a big thing also. That's why people buy from Timu and not Amazon. I mean, it's not - Do you want your Timu peptides? Wait, wait, but listen, I started to, Safe, I mean, that is the question. I started to tell Tim that there were a few people I knew who, do you remember Latisse, like the eyelash stuff? Yes. Super expensive, worked. But there was one you could buy online for like a fraction of the cost that was said to be the same stuff made in an emerging economy that will remain nameless India.
23:28And, you know, you could do that. I get the... But you don't, you, but we didn't. I get the knockoff toothbrush heads that are like the Amazon basics toothbrush heads. Oh, maybe I should look into that. For my electric toothbrush because they're like a tenth of the price. So what are you going to say? I'm not injecting that into my body. No, with this you were putting in your eye, essentially. But then it could go to your eyeball. Exactly. No, no, no. So it was a risk. Okay. But I'm not doing that. So how many people are doing this thing? I mean, so it's hard to tell. So we had to look for companies who were tracking it.
23:55So Chainalysis, for example, they tracked this and they looked at on-chain it. And you're talking specifically about the crypto side of this. So people are using the Bitcoin to buy this. Bitcoin to buy peptides from Chinese vendors. They've seen a 700 % year over year increase, which is a lot because I feel like now everyone talks about peptides, right? Like podcaster Jennifer Aniston said in 2023 that she was using peptides and that was three years ago. And we also quoted another one, TRM Labs. Wait, so GLP-1 is a peptide? It is. But these are other types of peptides. What's the difference? You really wouldn't say I'm taking peptide if you're taking GLP-1.
24:29You wouldn't. you wouldn't okay you're taking we govi you're taking ozampic technically they're peptides but you wouldn't say i'm taking but these drugs do the same thing or do you can get peptides that do weight loss but you can also get peptides that are supposed to improve muscle mass that are supposed to improve sleeping that are okay yeah okay sign me up i mean i'm just kidding i'm being facetious so okay so but it's happening it's happening and then the interest is just so So this is two stories. First, there's a peptide craze. And we went to an event. And it's Peptide 101. It went on for one hour.
25:02And it was really the basics of peptides. And I actually felt so impressed that people were there. And I was like, oh. So the brain rot that so many people are alluding to isn't happening. Because these are people who actively paid and attended to go and learn about something. And I have respect for that. And the whole talk was just about peptide. Nothing in relation to crypto. The crypto only comes in because a lot of these peptides are sold in the gray market. because they're maybe not the, I don't even want to say legitimate. What word did we use earlier? They're not the prescribed or traditional channels.
Read the full transcript
25:32So you can buy them in the gray market. And if you're in the gray market, you don't want to be traced. How do you pay? I mean, if it's like in another country, you can't really pay in cash. That's where crypto comes in. You got this great photo in your piece that shows Julius Ritter injecting himself at this peptide party. Who is Julius Ritter? This was a shocker. I mean, he is a 20-something-year-old. He is the president of California Peptide Club. And he said this himself, just like everyone in California. He's an AI startup founder, a longevity founder. And then in his introduction, he said, am I permitted to say this, Tim?
26:06If it's in the story, you can say it. He wanted me to say this, and I'm not going to do it. I guess I'm saying it. I'm going to save you, Carol. He said he's a sperm racer. What is that? Honestly, it is what it sounds like. it's an I don't know if it's an up and coming thing but it recently became a thing that boys men it is what it sounds like they raise their sperm and honestly I mean I think they take it as a sign of essentially the speed of it Carol New York Times had an article about it which is why I felt like mainstream media is right yes and people bet on it get out of my way if they could talk Carol That's how they would sound like.
26:49So I will push this more. This is a part of your story, so it's fair game. See, you wanted me to go there because you knew I would laugh. No, but listen, to be fair. He was very informed and he was really talking about the risks and the benefits. And again, someone was asking, what are the risks? And then he said, I'm paraphrasing, but no one has died from it based on his knowledge. So for him, the downside is much less. It plays with the wellness craze and wanting to be a better version of yourself. I guess it, yeah, it does. It has, the desire is there, but maybe the method of doing that is not necessarily.
27:24Yes. If you tell me there's something that will make me prettier, look younger, stronger, give me more muscles, I'm going to be like, yes, give that to me. And that's everything peptide promises. And that's what, that's what people are doing. They're ordering it. It's comes from unknown labs in China and they're injecting themselves with it. We're regulators. I mean, I guess not in the gray market. And maybe not in crypto. And Tim, you host a crypto show. And this is like one of the most enduring cases of crypto, right? Like that's why it can't seem to shake off their bad reputation. Isn't this the whole point of crypto though?
27:54Well, because that's the reality of it. Forgive me, but everything I still, I still don't go to the grocery store and use Bitcoin. I don't go on vacation and use Bitcoin. I don't get my salary in Bitcoin. So I don't pay healthcare in Bitcoin. So I just think, you know, it's the reality, right, of Bitcoin increasingly or the reality that's used in kind of, you know, illegal transactions. But this is what they always say, right? Bitcoin is not anonymous. It's pseudonymous, right? Is that the word? Pseudonymous, pseudonymous. It can be tracked. Yes, it can be tracked. You're not really anonymous.
28:34So I think you set your own risk goals. But I guess, again, it's a great market. So is this whole thing a boon for the companies like Coinbase, for example? Because this guy who you spoke to, Zach, he was really skeptical about crypto. And then he was like, you know what? I want these peptides. So I'm going to go and I'm going to create a Coinbase account. I'm going to convert some USD to Bitcoin. I'm going to send it to this lab and I'm going to get it. Possibly for now at the margins. It depends on how much volume they will see. But then this person we talked to, he never owned Bitcoin and he bought Bitcoin so he could buy a peptide.
29:05So he could do it. And now he said he reached his goal weight, so maybe he won't anymore. But then the point is it's attracting new users, whether they will be recurring. So again, it depends on the volume and all that, but it's attracting new users. I mean, it's easy. And that's the premise of Coinbase, right? They want to make owning crypto and others easy. So you just set up an account. You put your KYC and then you buy a Bitcoin. You order Peptide. You wait and then bam, it's in your doorstep. Bam, Tim. You do wonder if things like this, though, show people kind of how to transact with crypto.
29:35And then they start doing it for other things? Maybe. Yeah. Right? Like, you're like, okay, that made sense to me. I don't know. It's kind of easy to just take your phone out and put it on the payment terminal when you go buy something and your credit card gets charged. I know. Yeah, I agree. I don't disagree with you on that. But I don't know. But if it's something that isn't totally. That is true. Yeah. I mean, it's a good initiation, so to speak. And then until you get a taste of it. But back to this event, we talked to the people there and they were all new to peptide. And I was like, wow.
30:04I mean, it kind of has been around for a while, but I guess the mainstream craze. I mean, I've only recently heard of peptide in earnest this year, even if I've been talking about, I mean, in our reporting, we go V and all that, but this kind of peptide to make you pretty and all that I've only heard recently. And a lot of the people are like, yeah, I'm learning. They paid to go attend the event. Yeah. It was in New York City. Yes. And PubKey, which is a crypto themed bar. One of the podcasts that I listened to, that's like a not news podcast. one of the hosts had this idea that because so many people are injecting themselves with drugs that come from needles for like peptides and weight loss and stuff, there's like a market for a nice, pretty sort of needle collection container in your own home that you'd have.
30:46I see that. That's the world we live in. I get it. Yeah, because you should really dispose of those needles responsibly. Yeah, of course. Very responsibly. Maybe that could be a business for us, Tim. I'm staying completely away from this. I'll stick to, as Jay Powell used to say, I'll stick to my knitting. Fine, Carol and me, we can start the business. Okay, on it, on it, on it. Isabelle Lee, great story. Bloomberg News Cross Asset Reporter. Check it out. It's on the Bloomberg. Stay with us. More from Bloomberg Business Week Daily coming up after this.
31:19Support for the show comes from Public.com. If you're actively involved in your portfolio, you probably catch yourself repeating the same actions. Buying the dip, manually sweeping idle cash, putting on a hedge. On public, you can now create AI agents that handle all these tasks on your behalf. Just describe what you want to do in plain English. Like, if the VIX hits 25, buy a put option on the S &P 500. Or, if my cash balance goes above$20 ,000, move the excess into my direct index. You approve of the workflow and your agent handles the rest. Monitoring the market, watching for your conditions, and executing your strategies exactly as defined.
31:57An investing platform driven by your intent, not just your clicks. You can also get full read and write access to your account via the public API. Go to public.com slash market and fund your account in five minutes or less. That's public.com slash market. Paid for by Public Investing. Brokered services by Open to the Public Investing, Inc., member FINRA and SIPC. Advisory services by Public Advisors, LLC, SEC Registered Advisor. Complete disclosures available at public.com slash disclosures. If your best finance people are doing expense reports, chasing receipts, or spending time on month-end clothes, it's time to get Brex AF, a gentic finance that eliminates that work before it starts.
32:41Learn more at brex.com slash AF. Aging is real, and so are the benefits of adding vital proteins, collagen, peptides to your daily routine. Because around the age of 30, your body needs backup to keep your collagen up to help support healthy hair, skin, nails, bones, and joints. Available in the classic collagen peptides, collagen and protein shakes, and new Vital Proteins Collagen Sparkling Waters. So you can stay vital, stay you. Visit vitalproteins.com to learn more and where to buy. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
33:15You're listening to the Bloomberg Business Week Daily Podcast. Catch us live weekday afternoons from 2 to 5 Eastern. Listen on Apple CarPlay and Android Auto with the Bloomberg Business app. Or watch us live on YouTube. He's been hosting live streams on YouTube nearly every day. He offers off-the-cuff analysis on scores of companies, one after the next. He's asserted that only, quote, fools believe stocks go up over time and shorted SpaceX. He's discussed the intricacies of biotech drug development, while likening himself to Pablo Picasso. So he's ridiculed, ridiculed his viewers, too. He tells one to learn some English.
33:51And then he says, mother, effer, expletive. Mother finer? Sure. We're talking about Martin Shkreli, the so-called pharma bro, who's been called, quote, the most hated man in America. I want to get into this story. I do want to mention, though, a headline that was SpaceX to post their second quarter results on August 4th. I thought that was kind of interesting and kind of maybe perhaps, I don't know, maybe relevant. I don't know. Tell us. Thank you. I'll mark the calendar. Hey, we are marking the calendar on that one. Listen, this is so fascinating. Remind everybody, because we were marveling that like 10 years ago, it was nonstop and talking about this guy, figuring out how to pronounce his name and then talking about him nonstop.
34:30But remind the world in case they missed who this dude is. Yeah, so Martin Schickelli, for those who aren't familiar, really kind of rose to prominence in 2015. And that's after he decided to raise the price of an anti-parasitic drug that is life-saving, to be clear, by 5 ,000%. And after that, that kind of created a host of various problems and probes also from authorities. And that kind of allowed him to rise to prominence, to say the least. We got to see him throughout the trial spitballing, tweeting, despite pleading the fifth. There's just a lot of different things that happen. And now he's definitely back in the spotlight.
35:08We're speaking with Avalon Purnell, Bloomberg News Echities reporter. She writes this great story about Martin Shkreli being back and primed to fight to the bitter end. So how was your conversation with him for this story? Well, I can't say that we necessarily had a conversation. Why not? We did have an email exchange, that being said. Well, part of the reason why we did not get to have a conversation is that he did ask to be paid. And as you both know, that is against our company's policy. So we were not able to have a conversation, but definitely included that side bit into my story. I should note, this is, you know.
35:38What? Nobody pays. No news organization sort of like worth its salt or whatever would actually pay a source to have a conversation. So it's not just like, you know. It's just standard. Let me rephrase. This is standard policy. Yes. It should not come as a surprise to him, somebody who has been in the spotlight for many years. No, exactly. I mean, you know, we were also kind of just sharing, like, his story is just an interesting one. Like, every twist and turn. And here we are in another chapter that's also interesting. But, right, like, you were reminding us on the call about, like, all the stuff of his background.
36:16Yeah, Avalon, you get into it. Born in Brooklyn, the son of immigrants, did really well in high school. How did he find himself on, you know, on the wrong side of the law a decade ago? Well, I mean, even walking before that, I mean, he interned under the hedge fund that Jim Cramer previously was over. And at that point, he also really found his first love, which is shorting stocks. He had a very well-timed bearish bet on Regeneron. That did end up getting him probed. Obviously, everything ended up coming out to be fine for that one. But then he decided to open up his own hedge funds. Those kind of blew up.
36:51And we got to see a lot of legal troubles come and ensue after that situation. but definitely was very early on interested in finance and also in pharmaceuticals. Yeah, he's quite a character, right? And I really do feel like he's got a certain style, right, when it comes to how he addresses things and how he kind of justifies what he has done. So he's back. How is he back? Well, he has a lot of various things in his toolkit, to say the least. Part of it is the live streams, which can go from as long as like nine hours to as short as like two hours, which was today. It really just kind of depends.
37:28But he speaks on everything. Everything from like today, he spoke about relationship advice. Previously, he will also talk about like finance. Also, everything from like, oh, you should be long this stock. Maybe potentially these companies could be a short. It really just kind of depends on his mood. And all throughout it all, he has to be advertising his Goodell platform as well. Yeah. So you mentioned it. So talk about what that is. it's a competitor to the Bloomberg terminal. One thing that he likes to say that it's kind of sets itself differently from the Bloomberg terminal is that it does focus more on private companies as opposed to only like equities, which, I mean, we also obviously cover that as well, but it's just a slightly different target audience.
38:11We should know that Bloomberg LP is the, which offers the terminal as part of its suite of financial products is the parent company of Bloomberg News, including Bloomberg Radio and Bloomberg Media. Avalon, you and Carol, you said this like he's back. But I would argue after reading this story, he wouldn't be completely back until he unless he gets a pardon from the president. That is very true. So part of what happened after the case, he was banned from the pharmaceutical industry outright lifetime ban. And he's also barred from certain roles within the securities industry as well. And so he's definitely looking out for a pardon because that would allow him to rejoin the C-suite.
38:48He's actually currently consulting and advising a phototonics company that was previously a pharmaceutical company. And so if he does receive a pardon, then potentially he could actually reenter the C-suite and pursue various things, which he has tweeted about in the past as well. Remind us his track record. Is it good? It's like kind of random, right? It's a bit mixed, but at least when it comes to pharmaceuticals, he tends to be pretty good. I mean, we have one that he was fairly wrong on, like Capricorn, but a lot of his fans also tweeted at me as well about how Cassava was one where he did seem to be right.
39:22That was previously Celest Life Sciences. And so it just kind of depends on the company. But at least for some of these tech names that he's been diving into lately, I mean, some of them have actually gone down, like SpaceX or Intel. It just kind of depends on the day. What kind of response have you gotten? And I'm just curious for people weighing in because I do feel like he either has mega supporters or people who are pretty critical. Yes, it's definitely been, as you'd expect, definitely a mixed bag as well. Some people who are just like, oh, my gosh, I can't believe. What do you mean he's back?
39:51He's always been there for me. And when I spoke to some of his fans, they've also said that they've been looking out for him even throughout his prison stint the past decade. They've been very, very interested in everything that the Pharma Bro has been doing. And others are more so like, why are we focusing on him? What's going on? I know. He's been known to have back and forth with reporters online. I'm just wondering if you've heard from him after this story came out. Well, he did have one tweet out about his discord outside of that. Generally nothing. I will also say like one of his live streams, he did mention us as well.
40:24And so we'll see. Well, it's a great piece. And it was just fascinating to sort of blast from the past, but also to sort of understand what he's doing right now and how he has continued to have this following, even after being out of the spotlight for a few years in prison. Is the White House even considering a pardon? I mean, he has submitted an application. So in theory, he's going through the process. I can't speak on that specifically as to what that will look like. Well, what politically is he doing right now? What has he done with Republicans during the 2024 election? You get into that a little bit.
40:57Yeah, we definitely get into that slightly in terms of how he has been very publicly within the Twitter sphere, tweeting out against certain Democratic senators and other representatives. But aside from that, he's just been asking his followers to, you know, please put my name up, trying to say, generally speaking, like, okay, you can't pay for a pardon, but if you have any sort of ins or if you're in the know, then please help me out. So. 500 ,000 plus ex-followers. And then I guess his other stream, was it like 90 ,000 or something? Yes, but he has a web of YouTubes. There's Martin Shikelli, Mr.
41:34Shikelli, Shikelli Pill, Shikelli Planet. So he also has a lot of followers across the YouTube sphere as well. Avalon Purnell, Bloomberg News Echities reporter here in our Bloomberg Interactive Broker Studio. Check out her story. If you missed it, it's on the Bloomberg Terminal and at Bloomberg.com. This is the Bloomberg Businessweek Daily Podcast, available on Apple, Spotify, and anywhere else you get your podcasts. Listen live weekday afternoons from 2 to 5 p.m. Eastern on Bloomberg.com, the iHeartRadio app, TuneIn, and the Bloomberg Business app. You can also watch us live every weekday on YouTube and always on the Bloomberg Terminal.
42:23When you're running a business, the best days are the ones where priorities stay on track. For midsize and large companies, risk can affect multiple parts of the organization at once, from property and liability to cyber and regulatory challenges. At that level, managing risk becomes an ongoing discipline. At the Hartford, the focus is on helping businesses manage risk before it turns into something more disruptive. And when losses do happen, that work is paired with insurance coverage shaped by years of underwriting, risk engineering, and claims experience. Learn more at thehartford.com slash risk mitigation.
42:58Policies provided by Hartford Fire Insurance Company and its property and casualty affiliates, Hartford, Connecticut. Ask yourself, what are your best people spending their time on right now? Expense reports, receipt chasing, month-end close that takes weeks. You become what you spend on, and that's not what you're building toward. Brex is the intelligent finance platform that eliminates that work before it starts. AI agents that handle the manual stuff automatically. So your team can spend their time on what actually compounds. It's time to get Brex AF. Learn more at brex.com slash AF. Aging is real, and so are the benefits of new Vital Proteins Collagen Sparkling Water.
43:39Because around the age of 30, your body needs backup to keep your collagen up. So get your daily glow up, now in three fresh flavors. Strawberry blossom, lemon lime, and blood orange. Improved skin health in as little as 30 days thanks to collagen peptides? Cheers to that. So you can stay vital, stay you. Visit vitalproteins.com to learn more and where to buy. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
From the publisher
The people, companies and trends shaping the global economy. Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF.
A federal judge temporarily paused Paramount Skydance Corp.’s $110 billion takeover of Warner Bros. Discovery Inc. saying it “likely” violates antitrust law.
US District Judge Araceli Martínez-Olguín in Oakland on Monday ordered the companies to hold off on consummating the deal for 14 days. Paramount and Warner Bros. hoped to close as soon as July 22.California and 11 other states sued to block the Hollywood mega-merger on July 13. The states allege the deal, which seeks to combine two of the five largest studios, would harm competition for film and cable TV distribution.Paramount said it will continue to vigorously defend against the suit.
“We are confident the evidence will demonstrate that the state AGs’ antitrust arguments are without merit as their alleged markets and claims of anticompetitive effects are without any basis in modern market realities,” the company said in a statement. “This merger is lawful, pro-competitive, and will benefit consumers, creators, workers, and the entertainment industry.”
The judge scheduled an Aug. 3 hearing on whether to extend the hold for longer. The judge will decide whether to pause completion of the deal until after a trial to decide whether it is illegal under federal antitrust law.
On this episode, Carol Massar and Tim Stenovec speak with:
- Chris Palmeri, BN Media & Entertainment Team Lead
- Dina Esfandiary, Bloomberg Economics Middle East Geoeconomics Lead on 1,000 Days of War and Upheaval That Reshaped the Middle East
- Isabelle Lee, Bloomberg News Cross-Asset Reporter on Peptide ‘Wild West’ Pushes Everyday Americans Into Crypto
- Avalon Pernell BN Equities Reporter on Martin Shkreli Is Back and Primed to Fight ‘To the Bitter End’
See omnystudio.com/listener for privacy information.
